TRANSCEND CLL 004 study
TRANSCEND CLL 004 study
Related Articles
Management of complications of CAR T-cell therapies in Europe
We summarize results from a survey by the EBMT designed to assess the management of CAR T-cell complications in patients with ALL, lymphoma, and MM…
Symposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphoma
At the EHA 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint symposium on sequencing immune-based therapies in B-cell malignancies. Here,…
Lymphoma Hub Virtual Symposium
Customizing first-line BTK inhibitors for CLL. Wednesday, October 23, 2024, 18:30–19:30 BST
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, …
Lisocabtagene maraleucel vs standard of care as second-line therapy for LBCL: 3-year follow-up from the phase III TRANSFORM trial
We summarize results from the phase III TRANSFORM trial of liso-cel vs standard of care with salvage therapy followed by ASCT as second-line treatment for patients…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Outpatient administration of CAR T-cell therapies in patients with hematological malignancies
We summarize results from a retrospective analysis of reported outcomes of outpatient management of CAR T-cell therapies, with no remote monitoring and early intervention for…
Relmacabtagene autoleucel receives China NMPA supplementary biological application approval for R/R MCL
Following positive response data from the pivotal clinical trial in China, relmacabtagene autoleucel receives China NMPA supplementary biological application approval for the treatment of adult…